The University of Virginia seeks adults ages 18 and over with recurrent or metastatic endometrioid endometrial cancer. This study is studying 2 oral drugs: (1) hormonal agent and (2) targeted therapy agent
You may be eligible for this study if:
- You have grade 1 or 2 recurrent or metastatic endometrioid endometrial cancer
- You may have received prior lines of treatment (chemotherapy, radiation, immunotherapy, etc)
- You have measurable disease on Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)
This study involves Computed Tomograhpy (CT) exams, blood sample collection, and physical examination.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional Information can be found here: Study Details | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | ClinicalTrials.gov
No Compensation